February 2024 in “Skin research and technology” The research suggests that immune cells and a specific type of cell death called ferroptosis are involved in Frontal fibrosis alopecia.
45 citations
,
August 2005 in “Bioorganic & medicinal chemistry” New compounds with carborane showed anti-androgen effects similar to flutamide.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
8 citations
,
April 1991 in “European journal of endocrinology” 3α-AdiolG is a good marker for androgen activity in women with excessive hair growth and decreases with anti-androgen treatment.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
76 citations
,
July 2009 in “Neuroscience” Neurosteroids like allopregnanolone help control cell death and growth in the developing fetal brain.
October 2025 in “Annals of Medicine and Surgery” Retinoids may improve hair growth in androgenic alopecia when used with other treatments.
September 2024 in “Colloids and Surfaces B Biointerfaces” Cedrol nanoemulsions effectively treat hair loss by promoting hair growth and reducing DHT levels safely.
July 2022 in “Journal of Cosmetic Dermatology” Isotretinoin with tacrolimus may be more effective short-term for treating frontal fibrosing alopecia than finasteride with tacrolimus.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
October 2021 in “Scholarworks (University of Massachusetts Amherst)” FERONIA is crucial for plant growth, pollen tube reception, and sugar signaling.
9 citations
,
January 2024 in “International Journal of Dermatology” 1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine”
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
Sinapic acid and glabridin together help hair growth in androgenetic alopecia.
May 2024 in “Drug discovery today” Thyroid receptor β can help develop new drugs to treat hair loss.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Oral dutasteride is a recommended first treatment for frontal fibrosing alopecia.
4 citations
,
May 2022 in “Genes & Diseases”
5 citations
,
July 2003 in “Drug Development Research” Fluridil promotes hair growth safely and effectively for androgenetic alopecia.
9 citations
,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
34 citations
,
February 1993 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Certain 4-azasteroids are effective at blocking the enzyme that processes testosterone in human skin and could help treat acne, excessive hair growth, and male pattern baldness.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
114 citations
,
October 2006 in “Journal of the European Academy of Dermatology and Venereology” The new clobetasol propionate foam is effective and safe for treating alopecia areata.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
October 2025 in “International Journal of Risk & Safety in Medicine” Oral tofacitinib successfully treated a girl's severe skin and hair conditions.
12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.